PROCTER & GAMBLE SEPARATING OTCs FROM SKIN CARE BRANDS AS RATIONALIZATION OF PURCHASED BUSINESSES CONTINUES; THOMAS MOORE DUBBED HEAD OF OTC BUSINESS
Procter & Gamble is consolidating its basic OTC drug businesses under one management group and separating off the Rich-Vicks' skin care lines to a new beauty care division in a major restructuring announced May 10. The new Health Care Division (OTC) will be headed by Thomas Moore, currently VP of the Health and Personal Care Division. Under his control will fall the former OTC products of Rich-Vicks, Norwich and Searle. The range of products will stretch from cough-cold, to gastrointestinal, to oral care products. Among the brands in the new division will be Vick's Vaporub, Formula 44 cough mixtures, Nyquil, Percogesic, Metamucil, Pepto-Bismol, Crest, Scope and Gleem. The Health Care Division will presumably also be the vehicle for adopting Maalox from Rorer. Following the purchase of Rich-Vicks in 1985, P&G began to integrate the Rich-Vicks toiletries and OTC business into its operations in Cincinnati. In 1986, P&G assumed responsibility for Rich-Vicks' Sassoon and Pantene hair care lines, while Rich-Vicks took on P&G's skin care, cough/cold and analgesic products. In addition, responsibility for Rich-Vicks' oral care and gastrointestinal lines was transferred to P&G at that time. Moore, a 17-year P&G veteran, moved up through a variety of advertising positions before becoming general manager, Vidal Sassoon hair care, in 1986. He was elected to manager of the Health and Personal Care Division in 1987, and to his current post in 1988. Moore will report to Group VP Malcolm Jozoff, who will oversee the Health Care Division and continue as head of the firm's recently acquired Noxell cosmestics business. Jozoff reports to Exec VP Durk Jager, who will oversee both the newly formed Beauty Care and Health Care Divisions. In conjunction with the reorganization, top managers of three of the firm's operating subsidiaries have announced they are retiring June 30: Norwich Senior VP Harry Tecklenburg, Rich-Vicks VP William Bergman and Noxell President and Chief Operating Officer-Domestic Marvin Hathaway. Gilbert Cloyd, associate manager, Norwich Division, is being promoted to manager of the division, reporting to Jozoff. Cloyd joined P&G's research and development department in 1974; he was named Norwich director, product development, bone metabolism products in 1984, moving up to manager in 1985. He assumed his current duties in 1989. The Beauty Care Sector will consist of the new Beauty Care Division as well as the firm's recently acquired Noxell cosmetics division. P&G VP-Asia/Pacific Todd Garrett will be in charge of the Beauty Care Division. He also will report to Jager. The realigned Beauty Care Division will include skin care and personal cleansing products, hair care products and deodorants. Specifically, the division will house Rich-Vicks' Oil of Olay and Bain de Soleil lines, in addition to P&G's beauty products, including Head & Shoulders, Pert Plus, Ivory shampoo and conditioner and bar soap, Prell, Coast, Camay, Safeguard, Secret and Sure. Among the retiring execs, Tecklenburg worked in P&G's research and development area since 1952; he was elected VP-R&D in 1970, and senior VP in 1976. He has headed Norwich for six years. Bergman is retiring after 40 years with Rich-Vicks, most recently as president of Rich-Vicks USA. Hathaway has served with Noxell for 25 years, and has been a board member since 1972. He was named president and chief operating officer in 1986, moving up from exec VP and chief operating officer-domestic since 1984.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth